GlaxoSmithKline PLC (GSK) fair value: what the stock is really worth
As of Nov 5, 2026: fair value (intrinsic value) of GlaxoSmithKline PLC stock $69.24, price $50.41, upside +37.4%, quality 66 out of 100. Rating: undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range $24.52 – $59.60 · fair‑value band $44.20 – $91.70 · the $50.41 price screens below the $69.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow GlaxoSmithKline PLC ADR in your weekly email
Every Wednesday you see whether GlaxoSmithKline PLC ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Show moreShow less
It operates through Commercial Operations and Total R&D segments.
The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer.
It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus.
Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions.
It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases.
The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
Stock analysis
GlaxoSmithKline PLC (GSK) currently trades at $50.41, while our model-based Fair Value estimate is $69.24, implying the stock looks roughly 27% undervalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of $84.69 per share, and 19 of the 23 models we run sit above the $50.41 price.
Bear case: the Dividend Discount group reads lowest at $26.79, and 4 of the 23 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $44.20 (bear) to $91.70 (bull), the price of $50.41 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 66/100 (solid quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
GlaxoSmithKline PLC ADR reported revenue of £32.7B in FY2025 versus £24.7B in FY2021, a compound +7.2%/yr. Reported net income was £5.7B in FY2025, compounding +6.9%/yr from FY2021.
Key figures
Market cap $102B Large · P/E ratio 17.6 · P/S ratio 3.07 · EPS (TTM) $2.87 · Dividend yield 1.6% · Net margin 17.5% · Return on equity 28.3% · Return on assets (EBIT) 8.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 81 out of 100 (medium confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 15% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −11% fair-value upside, at 37%, GSK screens cheaper than that median.
Fair Value models
Bear$44.20Fair Value $69.24Bull$91.70
Price $50.41 · Upside +37.4%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then ($1.77 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF$44.61$72.67$117.7179
Growth DCF$46.38$72.54$112.6677
Owner Earnings$58.00$93.32$150.0075
All 23 models by family
DCF Models
FCF DCF$44.61$72.67$117.7179
Owner Earnings$58.00$93.32$150.0075
5Y Revenue Exit$39.17$64.23$95.3572
5Y EBITDA Exit$60.09$101.98$149.4874
5Y P/E Exit$47.41$79.10$111.1170
10Y Revenue Exit$39.13$62.72$92.5466
10Y EBITDA Exit$54.31$89.54$134.2467
10Y P/E Exit$46.00$73.29$104.6863
Earnings-Based
Graham-Dodd$26.18$66.85$86.9765
PEG = 1.0$12.48$17.82$23.1757
EPV$43.66$53.10$61.6274
Dividend Discount
Gordon GGM$16.93$35.73$69.4964
DDM Multi-Stage$16.93$26.79$38.4366
Multiples
P/E Multiple$63.52$84.69$105.8763
P/S Multiple$49.08$65.44$81.8158
EV/EBIT$61.97$85.83$109.7066
EV/EBITDA$75.47$103.83$132.1967
EV/Revenue$36.57$56.37$76.1753
Growth DCF
Growth DCF$46.38$72.54$112.6677
Rev-Margin DCF$39.17$64.61$92.4572
Economic Profit
Residual Income$22.84$27.77$47.8874
ROIC Compounder$46.34$59.95$75.1472
Growth Earnings
Growth-Adj P/E$49.09$70.12$91.1667
The fair value above starts from this blend and is adjusted for dilution from new shares.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.81/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+4.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.0%
Start year 2020 (pandemic). Over 10 years: +3.2% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
−4.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−5.6%
Dividend (yield on the price)1.6%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.15.5% vs 14.6%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.25% → 26%
2025 sits 132% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far and about what analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.1%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.5% a year for the price and +1.7% for the forecasts.
AI conclusion: GSK shows solid pricing power and organizational strength from scale and margins but limited signals on alignment and human capital point to only a moderate competitive moat.
Main risk: Loss of exclusivity on dolutegravir between 2028 and 2030 could allow generic rivals to erode sales and margins in the HIV franchise that accounted for over 17 percent of recent group turnover.
Bull case: Accelerated AI-supported R&D and targeted acquisitions could deliver new specialty medicines that replace lost HIV revenues and sustain growth into the 2030s.
Bear case: If the pipeline fails to offset the dolutegravir cliff and further legal or regulatory setbacks arise, revenues could stagnate while margins come under sustained pressure from generics and disputes.
GSK's specialty medicines grew 15 percent in Q3, led by HIV, oncology and respiratory products, while vaccines slipped. Fresh US approvals for Hibsago in hepatitis B and Jemperli in rectal cancer, plus 22 phase III trial starts planned for the year, show pipeline momentum. Our models see the shares as undervalued. Will the specialty push deliver more lasting growth than the vaccines segment can replace?
Compare GlaxoSmithKline PLC ADR with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks
Beats the industry median on 10/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score66 · Above median
Fair Value upside+37.4% · Top 25%
Profitability
Return on equity (12 months)28.3% · Top 25%
Return on assets9.4% · Above median
Net margin (12 months)13.0% · Above median
Operating margin (12 months)32.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)4.0% · Below median
Dividend yield (12 months)1.6% · Below median
Balance sheet
Debt / equity0.86× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
P/E (12 months)17.6× · Cheaper than median
P/B6.26× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is GlaxoSmithKline PLC (GSK) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of $69.24 versus a price of $50.41, about +37% upside (undervalued).
What is the fair value of GSK?
Our model-based fair value for GlaxoSmithKline PLC ADR is $69.24 (as of Nov 6, 2026), built from audited fundamentals. The current price: $50.41.
What is the quality score of GSK?
GlaxoSmithKline PLC ADR has a Quality Score of 66/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for GlaxoSmithKline PLC (GSK)?
Our model-based price target is the fair value of $69.24 (as of Nov 6, 2026) from 23 valuation models. Cautious scenario $44.20, optimistic scenario $91.70. It is a calculation from audited fundamentals, not an analyst target.
What is the GlaxoSmithKline PLC ADR stock forecast for 2026?
Our models put fair value at $69.24, about +37% upside versus a price of $50.41 (undervalued). Cautious scenario $44.20, optimistic scenario $91.70. The calculation is refreshed regularly with new filings.
What is the revenue of GlaxoSmithKline PLC (GSK)?
GlaxoSmithKline PLC ADR reported trailing-twelve-month revenue of about $33.5B (latest available figure, as of Nov 6, 2026).
Does GlaxoSmithKline PLC ADR pay a dividend?
GlaxoSmithKline PLC ADR currently shows a dividend yield of 1.57% relative to its recent price (as of Nov 6, 2026).
What growth is priced into GlaxoSmithKline PLC (GSK)?
For today's price to be fair in a discounted-cash-flow model, GlaxoSmithKline PLC ADR would have to grow free cash flow by +5.0 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.1 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of GSK use?
Our models discount GlaxoSmithKline PLC ADR at 8.1 %: a base by market capitalisation (large), damped by beta 0.28, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For GlaxoSmithKline PLC ADR that is +5.0 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has GlaxoSmithKline PLC (GSK) delivered so far?
Over the past 5 years revenue at GlaxoSmithKline PLC ADR grew +6.1 % a year. The price currently implies +5.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of GlaxoSmithKline PLC (GSK) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into GlaxoSmithKline PLC ADR (+5.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of GlaxoSmithKline PLC (GSK)?
The free-cash-flow yield on the price is 5.69 %: that much free cash flow GlaxoSmithKline PLC ADR produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of GlaxoSmithKline PLC (GSK)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For GlaxoSmithKline PLC ADR it is $69.24 per share (as of Nov 6, 2026), against a price of $50.41. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is GlaxoSmithKline PLC ADR stock overvalued or undervalued in 2026?
As of Nov 6, 2026, GSK trades below its calculated fair value: price $50.41, fair value $69.24, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GSK?
No. The price is what the market pays today ($50.41); the fair value is what the company's own numbers justify ($69.24). For GlaxoSmithKline PLC ADR the two are $18.83 per share apart. That gap is exactly why we show both numbers side by side.
How much is GlaxoSmithKline PLC ADR worth?
The market values GlaxoSmithKline PLC ADR at about $102B (market capitalisation, as of Nov 6, 2026). Per share that is $50.41; our models calculate a fair value of $69.24 per share.
What do the bullish and bearish scenarios say about GSK?
Our models span a range for GlaxoSmithKline PLC ADR: cautious scenario $44.20, base $69.24, optimistic $91.70 per share (as of Nov 6, 2026, price $50.41). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of GSK?
GlaxoSmithKline PLC ADR trades at a price-to-earnings ratio of 17.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $69.24 is built from several models across several years. Other multiples: PEG 5.9, P/B 6.3, P/S 3.1, EV/EBITDA 10.2.
What is the PEG ratio of GSK?
The PEG ratio of GlaxoSmithKline PLC ADR is 5.90 (P/E divided by earnings growth, as of Nov 6, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of GlaxoSmithKline PLC (GSK)?
Balance-sheet figures for GlaxoSmithKline PLC ADR (as of Nov 6, 2026): return on equity 28.3%, debt of 0.86 per unit of equity. They feed the Quality Score of 66/100, which measures business quality independently of the share price.
How far is GSK from its 52-week high?
GlaxoSmithKline PLC ADR trades at $50.41, about 15% below its 52-week high of $59.60 and 12% above the low of $44.92 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $69.24 is for.
Which stocks are comparable to GlaxoSmithKline PLC ADR?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is GlaxoSmithKline PLC ADR stock attractive at the current price?
The data as of Nov 6, 2026: price $50.41, calculated fair value $69.24 (+37%), Quality Score 66/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GSK calculated?
We run GlaxoSmithKline PLC ADR through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $69.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. GlaxoSmithKline PLC ADR currently trades 27% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of GlaxoSmithKline PLC (GSK)?
The closing price on Nov 5, 2026 was $50.41. Our model-based fair value is $69.24, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with GlaxoSmithKline PLC ADR right now?
Solid quality (66/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($44.20 to $91.70) leaves room in how you read the outcome.
Where does the earnings growth of GlaxoSmithKline PLC (GSK) come from?
Earnings per share at GlaxoSmithKline PLC ADR grew +2.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +4.1 %, EBIT margin −1.0 %, tax rate +0.7 %, residual (interest, one-offs) −1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of GlaxoSmithKline PLC ADR
How large is the market capitalisation of GlaxoSmithKline PLC (GSK)?
The market capitalisation of GlaxoSmithKline PLC ADR is $102B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of GlaxoSmithKline PLC (GSK)?
The price-to-sales ratio of GlaxoSmithKline PLC ADR is 3.07 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of GlaxoSmithKline PLC (GSK)?
Earnings per share at GlaxoSmithKline PLC ADR are $2.87 (price ÷ EPS = P/E 17.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of GlaxoSmithKline PLC (GSK)?
The dividend yield of GlaxoSmithKline PLC ADR is 1.6% (payout 27.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of GlaxoSmithKline PLC (GSK)?
The net margin of GlaxoSmithKline PLC ADR is 17.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of GlaxoSmithKline PLC (GSK)?
The return on equity (ROE) of GlaxoSmithKline PLC ADR is 28.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of GlaxoSmithKline PLC (GSK)?
On an EBIT basis the return on assets of GlaxoSmithKline PLC ADR is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of GlaxoSmithKline PLC (GSK)?
The operating margin of GlaxoSmithKline PLC ADR is 32.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at GlaxoSmithKline PLC (GSK)?
Revenue at GlaxoSmithKline PLC ADR is growing +4.0% versus a year earlier (3y avg +3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at GlaxoSmithKline PLC (GSK)?
Earnings per share at GlaxoSmithKline PLC ADR are growing −22.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does GlaxoSmithKline PLC (GSK) carry?
The net debt of GlaxoSmithKline PLC ADR is $14.3B (fiscal year 2025, ≈ 2.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch GlaxoSmithKline PLC ADR in the live analysis
One click puts GlaxoSmithKline PLC ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026